IWC - iShares Micro-Cap ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
107.4900
+1.3200 (+1.24%)
As of 2:38PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close106.1700
Open106.8600
Bid107.4300 x 800
Ask107.5300 x 800
Day's Range106.7200 - 107.4900
52 Week Range89.9200 - 110.1500
Volume12,038
Avg. Volume46,342
Net Assets1.14B
NAV109.97
PE Ratio (TTM)N/A
Yield0.93%
YTD Return15.30%
Beta (3y)1.05
Expense Ratio (net)0.60%
Inception Date2005-08-12
Trade prices are not sourced from all markets
  • ETF Database2 months ago

    This Week’s ETF Launches: AdvisorShares Partners with Dorsey Wright for New ETFs

    Dorsey Wright has been lending its investment expertise to ETF issuers for over a decade.

  • InvestorPlace3 months ago

    Sizing Up 4 Small-Cap ETFs

    Among domestic equities, small-caps have been the place to be this year. The iShares Russell 2000 ETF (NYSARCA:IWM), the largest exchange-traded fund (ETF) dedicated to smaller domestic stocks, is up nearly 9% year-to-date while the large-cap S&P 500 is higher by just 1.8%.

  • ETF Trends3 months ago

    Tiny Stocks, Big Gains for Micro-Cap ETF

    Small-cap stocks and related small-cap ETFs are on a torrid pace this year, but investors looking for even more exciting gains with ETFs tracking small companies may want to consider the iShares Micro-Cap ...

  • Benzinga3 months ago

    ETF Performance Reflects The Strength Of Micro-Caps In 2018

    Smaller stocks and corresponding exchange traded funds have recently been enjoying renewed fanfare and rightfully so. Year-to-date, the iShares Russell 2000 ETF (NYSE: IWM) is up 9.6 percent, or double the gains of the large-cap S&P 500. Smaller small-caps, or micro-caps, are performing even better.

  • Investopedia3 months ago

    Soaring No-Name Stocks Signal a Market Top

    Shares of microcap stocks have surged to  record highs, far outpacing the broader market, and that may be a bearish signal. According to Maley, since 2007 there have been six previous instances when the iShares Microcap ETF ( IWC) outperformed the S&P 500 Index (SPX) over the course of several months. The iShares Microcap ETF had an all-time record high close on June 6, up 12% year-to-date.

  • Investopedia4 months ago

    The Most Important Trends in the U.S. Stock Market Now

    The Nasdaq Composite, on the other hand, reached its upside objective of 7600 in January and has been consolidating below that level ever since. Was that the move, and now we reverse from this key extension target? Or should we instead focus on the fact that the Nasdaq just went out at an all-time monthly closing high, which is a characteristic of an uptrend, not a downtrend?

  • CNBC4 months ago

    Three ways to profit from the soaring dollar

    As the greenback soars to its highest levels of the year, one trader sees a couple of market areas that could ride the currency's coattails. "I will caution one thing" on the IWM, said Cappelleri. The U.S. dollar index has not traded above 94 since December 2017.

  • CNBC4 months ago

    Three ways to profit from the soaring dollar

    As the greenback soars to its highest levels of the year, one trader sees a couple of market areas that could ride the currency's coattails.

  • Comparing the Short Interest in the Top 5 OFS Companies
    Market Realist6 months ago

    Comparing the Short Interest in the Top 5 OFS Companies

    Top 5 Oilfield Companies Based on 2018 Returns

  • Analysts’ Recommendations for Cara Therapeutics in January 2018
    Market Realist8 months ago

    Analysts’ Recommendations for Cara Therapeutics in January 2018

    Cara Therapeutics (CARA) is a clinical-stage biopharmaceutical company focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by targeting peripheral kappa opioid receptors in affected patients. The company is developing a novel class of product candidates that target the body’s peripheral nervous system and certain immune cells. Of the seven analysts covering Cara Therapeutics in January 2018, six analysts gave the stock a “buy” or higher rating, and one recommended “hold.” The stock has a mean rating of 1.9 and a target price of $24.29.

  • Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases
    Market Realist8 months ago

    Arrowhead’s Candidates for Hepatitis B, Cardiovascular Diseases

    Arrowhead Pharmaceuticals: A Promising Drug Pipeline

  • Ignyta’s Drug Pipeline
    Market Realist8 months ago

    Ignyta’s Drug Pipeline

    Ignyta and Its Drug Candidates for 2018

  • Reawakening risk appetites
    CNBC Videos6 months ago

    Reawakening risk appetites

    CNBC's Mike Santoli takes a look at ETFs tracking some riskier sectors that investors are putting their faith into.